Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Sermonix Pharmaceuticals, a US-based biopharmaceutical company focused on metastatic breast and gynaecological cancers, has completed a $40m series A3 round led by Perceptive Advisors’ Xontogeny Ventures Fund II. The round included unnamed existing backers. Sermonix, which is based on research at Duke University, previously disclosed $26m in series A financing led by the Wild Family Office, with participation from private investors, in July 2019. The spinout had already raised nearly $1.6m in funding in July 2016, according to a regulatory…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).